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Q Does left atrial appendage 
closure reduce stroke rates as 
well as oral anticoagulants and 
antiplatelet meds in A-fib patients? 
EVIDENCE-BASED ANSWER
A Yes. Left atrial appendage closure  (LAAC) with the Watchman device 
is noninferior to vitamin K antagonists 
(VKAs) and non-VKA oral anticoagulants 
(NOACs) for adults with nonvalvular atrial 
fibrillation (NVAF) and 1 additional stroke 
risk factor (strength of recommendation 
[SOR]: A, multiple meta-analyses). 
LAAC has consistently been shown to 
be superior to antiplatelet therapy (SOR: A, 
single meta-analysis). One randomized 
controlled trial (RCT) demonstrated su-
periority of LAAC to VKA (SOR: B, single 
RCT).  
Evidence summary
A 2017 network meta-analysis included 
19 RCTs and 87,831 patients receiving anti-
coagulation, antiplatelet therapy, or LAAC 
for NVAF.1 LAAC was superior to antiplate-
let therapy (hazard ratio [HR]=0.44; 95% 
confidence interval [CI], 0.23-0.86; P<.05) 
and similar to NOACs (HR=1.01; 95% CI, 
0.53-1.92; P=.969) for reducing risk of 
stroke. 
LAAC and NOACs 
found “most effective”
A network meta-analysis of 21 RCTs, which 
included data from 96,017 patients, exam-
ined the effectiveness of 7 interventions 
to prevent stroke in patients with NVAF: 
4 NOACs, VKA, aspirin, and LAAC; the analy-
sis compared VKA with the other interven-
tions.2 The 2 trials that investigated LAAC 
accounted for only 1114 patients. 
When the 7 interventions were ranked si-
multaneously on 2 efficacy outcomes (stroke/
systemic embolism and all-cause mortality), 
all 4 NOACs and LAAC clustered together as 
“the most effective and lifesaving.” 
Fewer hemorrhagic strokes 
with LAAC than VKA
A 2016 meta-analysis of 6 RCTs compared 
risk of stroke for adults with NVAF who re-
ceived LAAC, VKA, or NOACs.3 No significant 
differences were found between NOACs and 
VKA or LAAC and VKA. The LAAC group had 
a significantly smaller number of patients. 
A 2015 meta-analysis of 2406 patients 
with NVAF found that patients who received 
LAAC had significantly fewer hemorrhagic 
strokes (HR=0.22; P<.05) than patients who 
received VKA.4 No differences in all-cause 
stroke were found between the 2 groups dur-
ing an average follow-up of 2.69 years.  
LAAC found superior to warfarin 
for stroke prevention in one trial
A 2014 multicenter, randomized study 
(PROTECT-AF) of 707 patients with NVAF 
plus 1 additional stroke risk factor compared 
LAAC with VKA (warfarin).5 LAAC met cri-
teria at 3.8 years for both noninferiority and 
superiority in preventing stroke, based on 
2.3 events per 100 patient-years compared 
with 3.8 events per 100 patient-years for VKA. 
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The number needed to treat with LAAC was 
67 to result in 1 less event per patient-year. 
A 2014 RCT (PREVAIL) evaluated pa-
tients with NVAF plus 1 additional stroke risk 
factor. LAAC was noninferior to warfarin for 
ischemic stroke prevention.6
Recommendations
The American College of Cardiology (ACC) 
recommends LAAC for patients with NVAF 
who are not candidates for long-term anti-
coagulation.7  Similarly, the 2016 European 
Society of Cardiology guidelines issued a 
Class IIb recommendation for LAAC for 
stroke prevention in those with contraindi-
cations for long-term anticoagulation.8  Last-
ly, in a 2014 guideline, the American Heart 
Association, ACC, and the Heart Rhythm 
Society issued a Class IIb recommendation 
for surgical excision of the left atrial append-
age in patients with atrial fibrillation under-
going cardiac surgery, but did not provide 
recommendations regarding LAAC.9         JFP
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